Increased endothelial activation in recently symptomatic versus asymptomatic carotid artery stenosis and in cerebral microembolic-signal-negative patient subgroups

Background and purpose von Willebrand factor propeptide (VWF:Ag II) is potentially a more sensitive marker of acute endothelial activation than von Willebrand factor antigen (VWF:Ag). These biomarkers have not been simultaneously assessed in asymptomatic versus symptomatic carotid stenosis patients....

Full description

Saved in:
Bibliographic Details
Published in:European journal of neurology Vol. 21; no. 7; pp. 969 - e55
Main Authors: Kinsella, J. A., Tobin, W. O., Kavanagh, G. F., O'Donnell, J. S., McGrath, R. T., Tierney, S., Feeley, T. M., Egan, B., O'Neill, D., Collins, R. D., Coughlan, T., Harbison, J. A., Doherty, C. P., Madhavan, P., Moore, D. J., O'Neill, S. M., Colgan, M.-P., Saqqur, M., Murphy, R. P., Moran, N., Hamilton, G., McCabe, D. J. H.
Format: Journal Article
Language:English
Published: England Blackwell Publishing Ltd 01-07-2014
John Wiley & Sons, Inc
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and purpose von Willebrand factor propeptide (VWF:Ag II) is potentially a more sensitive marker of acute endothelial activation than von Willebrand factor antigen (VWF:Ag). These biomarkers have not been simultaneously assessed in asymptomatic versus symptomatic carotid stenosis patients. The relationship between endothelial activation and cerebral microembolic signals (MESs) detected on transcranial Doppler ultrasound is unknown. Methods In this multicentre observational analytical study, plasma VWF:Ag and VWF:Ag II levels in patients with ≥50% asymptomatic carotid stenosis were compared with those from patients with ≥50% symptomatic carotid stenosis in the ‘early’ (≤4 weeks) and ‘late’ (≥3 months) phases after transient ischaemic attack or ischaemic stroke. Endothelial activation was also longitudinally assessed in symptomatic patients during follow‐up. Transcranial Doppler ultrasound monitoring classified patients as MES‐positive or MES‐negative. Results Data from 31 asymptomatic patients were compared with those from 46 early symptomatic and 35 late phase symptomatic carotid stenosis patients, 23 of whom had undergone carotid intervention. VWF:Ag II levels were higher in early (12.8 μg/ml; P < 0.001), late (10.6 μg/ml; P = 0.01) and late post‐intervention (10.6 μg/ml; P = 0.038) symptomatic patients than asymptomatic patients (8.9 μg/ml). VWF:Ag levels decreased in symptomatic patients followed up from the early to late phase after symptom onset (P = 0.048). Early symptomatic MES‐negative patients had higher VWF: Ag II levels (13.3 vs. 9.0 μg/ml; P < 0.001) than asymptomatic MES‐negative patients. Conclusions Endothelial activation is enhanced in symptomatic versus asymptomatic carotid stenosis patients, in early symptomatic versus asymptomatic MES‐negative patients, and decreases over time in symptomatic patients. VWF:Ag II levels are a more sensitive marker of endothelial activation than VWF:Ag levels in carotid stenosis. The potential value of endothelial biomarkers and concurrent cerebral MES detection at predicting stroke risk in carotid stenosis warrants further study.
Bibliography:ArticleID:ENE12403
Lundbeck Neurosciences Bursary
Brennan and Company, Ireland
ark:/67375/WNG-4N1V9PP5-1
istex:57E7BA2D0CADE39601CBDEA8A7C4322DF214D995
Elitech UK
Biogen Idec Ireland Limited
Research in Third Level Institutions
Meath Foundation
Merck Serono Ireland
Table S1. Demographic data and risk factor profiles of study patients with available TCD data. Table S2. Comparison of endothelial activation in asymptomatic versus early symptomatic and late phase symptomatic carotid stenosis patients who were MES-negative.
Stanley Thomas Johnson Foundation
Pfizer Ireland
Bayer Schering Ireland
IICN-Serono
European Regional Development Fund
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Undefined-2
ObjectType-Article-2
ObjectType-Feature-1
ISSN:1351-5101
1468-1331
DOI:10.1111/ene.12403